5TQ3

Design and Synthesis of a pan-JAK kinase inhibitor clinical candidate (PF-06263276) suitable for the treatment of inflammatory diseases of the lungs and skin

5TQ3 の概要

• エントリーDOI: 10.2210/pdb5tq3/pdb
• 関連するPDBエントリー: 5TQ4 5TQ5 5TQ6 5TQ7 5TQ8
• 分子名称: Tyrosine-protein kinase JAK2, 4-[3-(1H-benzimidazol-2-yl)-1H-indazol-6-yl]-3-ethylphenol (3 entities in total)
• 機能のキーワード: kinase, inflammation, jak inhibitor, transferase-transferase inhibitor complex, transferase/transferase inhibitor
• 由来する生物種: Homo sapiens (Human)
• 細胞内の位置: Endomembrane system ; Peripheral membrane protein : O60674
• タンパク質・核酸の鎖数: 2
• 化学式量合計: 72494.12

構造登録者

Chrencik, J.,Jones, P. (登録日: 2016-10-23, 公開日: 2017-01-11, 最終更新日: 2023-11-15)

• 主引用文献: Jones, P.,Storer, R.I.,Sabnis, Y.A.,Wakenhut, F.M.,Whitlock, G.A.,England, K.S.,Mukaiyama, T.,Dehnhardt, C.M.,Coe, J.W.,Kortum, S.W.,Chrencik, J.E.,Brown, D.G.,Jones, R.M.,Murphy, J.R.,Yeoh, T.,Morgan, P.,Kilty, I.; Design and Synthesis of a Pan-Janus Kinase Inhibitor Clinical Candidate (PF-06263276) Suitable for Inhaled and Topical Delivery for the Treatment of Inflammatory Diseases of the Lungs and Skin.; J. Med. Chem., 60:767-786, 2017; PubMed: 27983835; DOI: 10.1021/acs.jmedchem.6b01634

実験手法

X-RAY DIFFRACTION (2.69 Å)